Rocket One Inc. Common Stock (NASDAQ:RKTO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) from a strong sell rating to a sell rating in a report issued on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings downgraded shares of Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, October 14th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $5.00.

Rocket One Inc. Common Stock Trading Up 5.4%

Rocket One Inc. Common Stock stock opened at $0.54 on Friday. The stock has a fifty day moving average price of $0.68 and a two-hundred day moving average price of $0.86. Rocket One Inc. Common Stock has a 52-week low of $0.48 and a 52-week high of $2.45.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last issued its earnings results on Friday, August 14th. The company reported ($0.19) EPS for the quarter.

Institutional Investors Weigh In On Rocket One Inc. Common Stock

An institutional investor recently raised its position in Rocket One Inc. Common Stock stock. Lido Advisors LLC boosted its holdings in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) by 100.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,000 shares of the company’s stock after purchasing an additional 19,500 shares during the period. Lido Advisors LLC owned 0.20% of Rocket One Inc. Common Stock worth $33,000 as of its most recent SEC filing. 7.08% of the stock is owned by hedge funds and other institutional investors.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.